CellCept, Mycophenolate Newswire

CellCept, Mycophenolate Newswire

Comprehensive Real-Time News Feed for CellCept, Mycophenolate (generic).

Results 1 - 20 of 99 in CellCept, Mycophenolate (generic)

  1. Technology improves clinical trial management and patient experienceRead the original story w/Photo

    Wednesday Jul 20 | PhysOrg Weblog

    The University of Alabama at Birmingham recently integrated a clinical research management system that allows patient consent, data and documents from multiple sites to automatically flow from the the Enroll e-Consenting tablet application by Mytrus into the Velos eResearch interface. "The interface takes the UAB initiative to use more 'direct-to-participant' methods one step further," said Jeffrey Curtis, M.D., William J. Koopman Professor of Medicine in the UAB Division of Clinical Immunology and Rheumatology.

    Comment?

  2. Video: How much protein do you need to build muscle?Read the original story w/Photo

    Tuesday Jul 19 | PhysOrg Weblog

    While this is obvious to many athletes and gym-goers, the biological and chemical processes between drinking a protein shake and getting "swole" may not be so clear. Reactions has you covered - find out how much protein is recommended for athletes and what makes muscles grow in our latest video: Autopsies have shown that some high-profile athletes who suffered repeated blows to the head during their careers have unusual protein clumps in their brains.

    Comment?

  3. Global and China Mycophenolate Acid Market Trends and Key Manufacturers Overview 2016-2021Read the original story

    Friday Jul 15 | Emailwire.com

    Reportsweb.com adds "Global Mycophenolate Acid Industry 2016 Market Research Report" to its store. The report introduced Molten Carbonate fuel Cell new project SWOT analysis, investment feasibility analysis, and investment return analysis and Mycophen 2016 Mycophenolate Acid Industry - Global and Chinese Market Scenario is a professional and in-depth study on the current state of the global Mycophenolate Acid industry with a focus on the Chinese market.

    Comment?

  4. Young and well educated men in demand as sperm donors in global life marketRead the original story w/Photo

    Thursday Jul 7 | PhysOrg Weblog

    A world-first QUT study reveals the age and education of sperm donors are the most imporant characteristics considered. Credit: Queensland University of Technology With commercial sperm banking giving women more opportunities to become mothers, a world-first QUT study has found the age and education of sperm donors are the most important characteristics considered.

    Comment?

  5. Combining technologies cracks vaccine chiller issueRead the original story w/Photo

    Wednesday Jul 6 | PhysOrg Weblog

    Vaccines against killer diseases from polio to hepatitis are fragile and can easily be made useless if they get too hot or too cold. The problem is particularly acute in the developing countries where nearly one in five of the world's population - 1.3 billion people - live without access to electricity.

    Comment?

  6. New strategy treats fatal autoimmune disease without outward off-target effectsRead the original story w/Photo

    Monday Jul 4 | Medical News

    In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system. The autoimmune disease the team studied is called pemphigus vulgaris , a condition in which a patient's own immune cells attack a protein called desmoglein-3 that normally adheres skin cells.

    Comment?

  7. Is Aurinia Pharmaceuticals Going To Revolutionize The Treatment Of Lupus Nephritis?Read the original story w/Photo

    Friday Jul 1 | Seeking Alpha

    In a small clinical study, the combination of voclosporin with standard of care resulted in a 57% complete remission rate, which is much higher than current standard of care. We consider this company undervalued at its current stock price and initiate coverage with a Buy rating and long-term price target = $8.73 to $14.38.

    Comment?

  8. New therapy treats autoimmune disease without harming normal immunityRead the original story w/Photo

    Friday Jul 1 | Medical News Today

    Preclinical study from Penn shows that engineered T cells can selectively target the antibody-producing cells that cause autoimmune disease. In a study with potentially major implications for the future treatment of autoimmunity and related conditions, scientists from the Perelman School of Medicine at the University of Pennsylvania have found a way to remove the subset of antibody-making cells that cause an autoimmune disease, without harming the rest of the immune system.

    Comment?

  9. Press release distribution, EDGAR filing, XBRL, regulatory filingsRead the original story w/Photo

    Wednesday Jun 29 | Business Wire

    The 'Global and Chinese ALES Ind... )--FUND A db x-trackers MSCI World Consumer Discretionary Index UCITS ETF DEALING DATE A 28-Jun-16 NAV PER SHARE A USD22.4718 NUMBER OF SHARES IN ISSUE A 5137672 CODE A )--Research and Markets has announced the addition of the "Global and Chinese Fatty Acids,Rape-Oil,Potassium Salts Industry - 2016" report to their offering. The 'Global and C... )--29 June 2016 Issue: Vodafone Group Plc 56 XS1386298563 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate det... )--A.M. Best has affirmed the financial strength rating of B+ and the issuer credit rating of "bbb-" of DPL Insurance Limited .

    Comment?

  10. Aurinia Announces 24 Week Remission Rates From The First Seven...Read the original story

    Tuesday Jun 28 | BioSpace

    Aurinia Announces 24 Week Remission Rates From The First Seven Patients In Its Open Label AURION Study In Lupus Nephritis VICTORIA, British Columbia-- --Aurinia Pharmaceuticals Inc. announced today that it has completed an analysis of the first 7 patients to complete 24 weeks in its open-label AURION study. At 24 weeks 57% of patients continued to be in complete remission as measured by a urinary protein creatinine ratio of = 0.5mg/mg, eGFR within 20% of baseline and concomitant steroid dose of less than 5mg/day.

    Comment?

  11. Industry-academia publication agreements include limits on publication of trial resultsRead the original story w/Photo

    Tuesday Jun 28 | PhysOrg Weblog

    Publication agreements constraining academic investigators' independence are common, and incompletely reported in publications, according to a study published in this week's PLOS Medicine . The study, conducted by Matthias Briel, University Hospital Basel, Switzerland, and colleagues, suggests that publication agreements may compromise the scientific evidence base established by randomized clinical trials.

    Comment?

  12. Lack of voluntary data sharing from industry-funded clinical trialsRead the original story w/Photo

    Tuesday Jun 28 | PhysOrg Weblog

    In a study appearing in the June 28 issue of JAMA , Isabelle Boutron, M.D., Ph.D., of Paris Descartes University, Paris, and colleagues investigated the proportion of randomized clinical trials registered at ClinicalTrials.gov that were listed at the Clinical Study Data Request website, where companies voluntarily list studies for which data can be requested. Access to individual patient-level data from clinical trials could be an important step forward in clinical research.

    Comment?

  13. Organ Transplant Immunosuppressant Drugs Market to reach USD 4.4 Billion by 2020Read the original story w/Photo

    Friday Jun 24 | PR Log

    MARYLAND HEIGHTS, Mo. - June 24, 2016 - PRLog -- According to a market research report published by iHealthcareAnalyst, Inc., Organ Transplant Immunosuppressant Drugs Market - Global Immunosuppressant Drug Classes and Organ Types Analysis and Forecast 2013-2020 for key market segments based on the drug classes and transplanted organ types , and forecasts growth trends .

    Comment?

  14. Reforming clinical research to reduce wasteRead the original story w/Photo

    Jun 21, 2016 | PhysOrg Weblog

    Many billions of dollars are spent on clinical research every year, yet much of the knowledge produced is not useful for guiding clinical decision making. Because many of the features that make clinical research reliable as a basis for clinical practice can be identified, more useful clinical research could easily be produced at the same or even at massively reduced cost, according to John Ioannidis from Stanford University, US, in an Essay published in PLOS Medicine .

    Comment?

  15. Assisted dying for psychiatric disorders: Serious public health impactRead the original story w/Photo

    Jun 21, 2016 | PhysOrg Weblog

    Offering medical assistance in dying to people in Canada on the basis of psychiatric illnesses could put vulnerable people at risk, argues a commentary in CMAJ . "There is a serious gap between the idealized basis upon which assisted dying for patients with psychiatric conditions is advocated and the reality of its practice, as reflected in evidence from Belgium and the Netherlands.

    Comment?

  16. Corbus Pharmaceuticals Announces Last Patient Enrolled in Phase 2 Study of Resunab for...Read the original story w/Photo

    Jun 16, 2016 | Freshnews

    Corbus Pharmaceuticals Holdings, Inc. , a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that it has completed patient enrollment in its Phase 2 clinical trial of Resunab for the treatment of diffuse cutaneous systemic sclerosis . The Company expects to report top-line results from this study in the fourth quarter of 2016.

    Comment?

  17. Antibody-based drug helps 'bridge' leukemia patients to curative treatmentRead the original story w/Photo

    Jun 12, 2016 | PhysOrg Weblog

    In a randomized Phase III study of the drug inotuzumab ozogamicin, a statistically significant percentage of patients with acute lymphoblastic leukemia whose disease had relapsed following standard therapies, qualified for stem cell transplants. Inotuzumab ozogamicin, also known as CMC-544, links an antibody that targets CD22, a protein found on the surface of more than 90 percent of ALL cells.

    Comment?

  18. Aurinia Announces Results Of Annual General MeetingRead the original story

    Jun 9, 2016 | BioSpace

    Aurinia Pharmaceuticals Inc. is pleased to announce that the six incumbent directors of the Company were re-elected at the Company's annual general meeting held on June 8, 2016 . Voting results on all matters voted on at the Meeting will be filed on SEDAR at www.sedar.com and EDGAR at www.edgar.com .

    Comment?

  19. Greatly reduced risk of EBV reactivation in rituximab-experienced...Read the original story

    Jun 1, 2016 | Bone Marrow Transplantation

    Correspondence: Dr DM Burns, Centre for Clinical Haematology, University Hospitals Birmingham NHS Trust, Birmingham B15 2TH, UK. Email: [email protected] EBV-associated post-transplant lymphoproliferative disease remains an important complication of allogeneic haematopoietic stem cell transplantation .

    Comment?

  20. Liver Transplantation Market Value Share and Key Trends 2016-2026Read the original story w/Photo

    May 31, 2016 | SBWire

    Liver transplantation or hepatic transplantation is a surgical procedure performed when the liver fails to perform its normal functions such as synthesis of carbohydrates, proteins and fats. The liver is the second most commonly transplanted major organ, after the kidney, so it is clear that liver disease is a common and serious problem.

    Comment?